progression-free survival

progression-free survival

,

PFS

In cancer care, the time during which a patient shows no signs or symptoms of the growth or the spreading of a tumor.
References in periodicals archive ?
For the primary end point of progression-free survival, the combination-therapy arm showed twice the benefit of the monotherapy arm: 4.
1-month progression-free survival from that time, compared with 7.
Encouraging Objective Response Rate and Progression-Free Survival Estimate Reported in Abstract
In the completed Phase 2 ENCORE 301 study, entinostat was shown to extend both progression-free survival and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) metastatic breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor.
Regorafenib plus BSC significantly improved progression-free survival compared to placebo plus BSC.
We've pretty much increased threefold progression-free survival in our patients, and we have achieved significant improvement in median survival, which is meaningful for our patients," Dr.
Data Presented at Congress of Neurological Surgeons Annual Meeting Shows ICT-107 Extends Progression-Free Survival Time in Glioblastoma Patients By More Than One Year
1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the second-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, a targeted treatment that increases the median progression-free survival relative to a regimen of GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb and Roche/Chugai's Xeloda would earn similar patient share in the U.
Seven of the 16 newly-diagnosed patients demonstrated stable disease with median progression-free survival of 64 weeks, and three of these seven patients have progression-free survival of over two years.
Importantly, Rexin-G improved patient survival in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median progression-free survival was greater than 3 months, and median over-all survival was greater than 9 months.
The two groups had similar progression-free survival (IHA 7.